Pub Date : 2024-02-07DOI: 10.2174/0115733947289878240126111236
Kavita Sangwan, Parveen Kumar Goyal
Flavonoids, one of the major bioactive constituents of herbal drugs, have been scientifically reported to possess diverse therapeutic potentials such as anticancer, immunomodulatory, neuroprotective, cardioprotective, antioxidant, etc. This manuscript enlightens the anticancer potential of traditional herbal flavonoids in gynecological cancer i.e., is one of the major life-threats in women. This manuscript is aimed at an insightful compilation of scientific substantiations of herbal flavonoids in gynecological cancer along with targeted drug delivery systems for the same. The contents and data represented in the article have been reviewed using institutional libraries and online database resources (available in the public domain) such as PubMed, Science-Direct, Web of Science, American Association of Pharmaceutical Scientists, Google Scholar, Hinari, SciFinder, Research Gate, etc. Flavonoids are natural compounds and have potential against cervical, ovarian, and endometrial cancer. In-vitro and in-vivo experiments have demonstrated the significant potential of flavonoids in gynecological cancer, especially cervical, ovarian, and endometrial cancer. It was reported from in-vitro experimentations that targeted drug delivery system improves the anticancer effect of flavonoids. Phytoflavonoids have the potential to prevent gynecological cancer by induction of apoptosis cell cycle arrest and reactive oxygen species generation. Further studies on the drug delivery system of flavonoids are warranted.
据科学报道，黄酮类化合物是中草药的主要生物活性成分之一，具有抗癌、免疫调节、神经保护、心脏保护、抗氧化等多种治疗潜力。本手稿揭示了传统草药黄酮类化合物在妇科癌症中的抗癌潜力、本手稿旨在深入汇编草本黄酮类化合物在妇科癌症中的科学证据，以及针对妇科癌症的靶向给药系统。文章中的内容和数据已通过机构图书馆和在线数据库资源（可在公共领域获取）进行了审查，如 PubMed、Science-Direct、Web of Science、美国医药科学家协会、Google Scholar、Hinari、SciFinder、Research Gate 等。体外和体内实验证明，黄酮类化合物对妇科癌症，尤其是宫颈癌、卵巢癌和子宫内膜癌具有显著的抗癌潜力。据体外实验报告，靶向给药系统提高了黄酮类化合物的抗癌效果。植物黄酮类化合物可通过诱导细胞凋亡、细胞周期停滞和活性氧生成来预防妇科癌症。关于类黄酮的给药系统还有待进一步研究。
{"title":"Anti-cancer Potential of Phytoflavonoidal Drugs against Gynecological\u0000Cancer","authors":"Kavita Sangwan, Parveen Kumar Goyal","doi":"10.2174/0115733947289878240126111236","DOIUrl":"https://doi.org/10.2174/0115733947289878240126111236","url":null,"abstract":"\u0000\u0000Flavonoids, one of the major bioactive constituents of herbal drugs, have\u0000been scientifically reported to possess diverse therapeutic potentials such as anticancer, immunomodulatory, neuroprotective, cardioprotective, antioxidant, etc. This manuscript enlightens the anticancer\u0000potential of traditional herbal flavonoids in gynecological cancer i.e., is one of the major life-threats\u0000in women.\u0000\u0000\u0000\u0000This manuscript is aimed at an insightful compilation of scientific substantiations of herbal\u0000flavonoids in gynecological cancer along with targeted drug delivery systems for the same.\u0000\u0000\u0000\u0000The contents and data represented in the article have been reviewed using\u0000institutional libraries and online database resources (available in the public domain) such as PubMed,\u0000Science-Direct, Web of Science, American Association of Pharmaceutical Scientists, Google Scholar,\u0000Hinari, SciFinder, Research Gate, etc.\u0000\u0000\u0000\u0000Flavonoids are natural compounds and have potential against cervical, ovarian, and endometrial cancer. In-vitro and in-vivo experiments have demonstrated the significant potential of flavonoids in gynecological cancer, especially cervical, ovarian, and endometrial cancer. It was reported\u0000from in-vitro experimentations that targeted drug delivery system improves the anticancer effect of\u0000flavonoids.\u0000\u0000\u0000\u0000Phytoflavonoids have the potential to prevent gynecological cancer by induction of\u0000apoptosis cell cycle arrest and reactive oxygen species generation. Further studies on the drug delivery system of flavonoids are warranted.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"90 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139794793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-01DOI: 10.2174/0115733947256172231128064128
Naina Kumar, I. Pradeep, Annapurna Srirambhatla, K. Poojitha, M. Mangla
Bordeline Brenner tumors of the ovary are rare tumors accounting for 2% of all ovarian tumors and are characterized by the presence of papillary structures covered with transitional epithelium without or minimal stromal invasion. In the present case report a 60-year-old postmenopausal woman presented with complaints of lower abdominal pain and a right ovarian mass of 4x5cm, which was diagnosed on histopathological examination as borderline Brenner tumor of the ovary. There were coexisting nonatypical endometrial hyperplasia and endocervical polyps of 1.2x0.9x0.6cm, indicating endometrial hyperstimulation as a result of estrogen secreted by the tumor. The patient was managed successfully with staging laparotomy and was diagnosed with stage I borderline Brenner tumor with non-atypical endometrial hyperplasia and benign endocervical polyp. Borderline Brenner tumors are rare tumors of ovaries with uncertain malignant potential. They have no precise predictive markers but are known to produce estrogen. Surgery remains the mainstay of treatment for these tumors.
在本病例报告中，一名 60 岁的绝经后妇女主诉下腹痛，右侧卵巢肿块 4x5 厘米，经组织病理学检查确诊为卵巢边界布伦纳肿瘤。患者同时伴有非典型子宫内膜增生和 1.2x0.9x0.6cm 的宫颈内膜息肉，表明肿瘤分泌的雌激素导致子宫内膜过度刺激。患者通过分期开腹手术成功接受了治疗，被诊断为边缘布伦纳肿瘤 I 期，伴有非典型子宫内膜增生和良性宫颈内膜息肉。边缘布伦纳肿瘤是一种罕见的卵巢肿瘤，恶性潜能不确定。手术仍是治疗这些肿瘤的主要方法。
{"title":"Borderline Brenner Tumor of the Ovary in a Postmenopausal Woman: A\u0000Rare Case with Concomitant Endometrial Hyperplasia and Endocervical\u0000Polyp","authors":"Naina Kumar, I. Pradeep, Annapurna Srirambhatla, K. Poojitha, M. Mangla","doi":"10.2174/0115733947256172231128064128","DOIUrl":"https://doi.org/10.2174/0115733947256172231128064128","url":null,"abstract":"\u0000\u0000Bordeline Brenner tumors of the ovary are rare tumors accounting for 2% of\u0000all ovarian tumors and are characterized by the presence of papillary structures covered with transitional\u0000epithelium without or minimal stromal invasion.\u0000\u0000\u0000\u0000In the present case report a 60-year-old postmenopausal woman presented with\u0000complaints of lower abdominal pain and a right ovarian mass of 4x5cm, which was diagnosed on histopathological\u0000examination as borderline Brenner tumor of the ovary. There were coexisting nonatypical\u0000endometrial hyperplasia and endocervical polyps of 1.2x0.9x0.6cm, indicating endometrial\u0000hyperstimulation as a result of estrogen secreted by the tumor. The patient was managed successfully\u0000with staging laparotomy and was diagnosed with stage I borderline Brenner tumor with non-atypical\u0000endometrial hyperplasia and benign endocervical polyp.\u0000\u0000\u0000\u0000Borderline Brenner tumors are rare tumors of ovaries with uncertain malignant potential.\u0000They have no precise predictive markers but are known to produce estrogen. Surgery remains the\u0000mainstay of treatment for these tumors.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139821541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-01DOI: 10.2174/0115733947256172231128064128
Naina Kumar, I. Pradeep, Annapurna Srirambhatla, K. Poojitha, M. Mangla
Bordeline Brenner tumors of the ovary are rare tumors accounting for 2% of all ovarian tumors and are characterized by the presence of papillary structures covered with transitional epithelium without or minimal stromal invasion. In the present case report a 60-year-old postmenopausal woman presented with complaints of lower abdominal pain and a right ovarian mass of 4x5cm, which was diagnosed on histopathological examination as borderline Brenner tumor of the ovary. There were coexisting nonatypical endometrial hyperplasia and endocervical polyps of 1.2x0.9x0.6cm, indicating endometrial hyperstimulation as a result of estrogen secreted by the tumor. The patient was managed successfully with staging laparotomy and was diagnosed with stage I borderline Brenner tumor with non-atypical endometrial hyperplasia and benign endocervical polyp. Borderline Brenner tumors are rare tumors of ovaries with uncertain malignant potential. They have no precise predictive markers but are known to produce estrogen. Surgery remains the mainstay of treatment for these tumors.
在本病例报告中，一名 60 岁的绝经后妇女主诉下腹痛，右侧卵巢肿块 4x5 厘米，经组织病理学检查确诊为卵巢边界布伦纳肿瘤。患者同时伴有非典型子宫内膜增生和 1.2x0.9x0.6cm 的宫颈内膜息肉，表明肿瘤分泌的雌激素导致子宫内膜过度刺激。患者通过分期开腹手术成功接受了治疗，被诊断为边缘布伦纳肿瘤 I 期，伴有非典型子宫内膜增生和良性宫颈内膜息肉。边缘布伦纳肿瘤是一种罕见的卵巢肿瘤，恶性潜能不确定。手术仍是治疗这些肿瘤的主要方法。
{"title":"Borderline Brenner Tumor of the Ovary in a Postmenopausal Woman: A\u0000Rare Case with Concomitant Endometrial Hyperplasia and Endocervical\u0000Polyp","authors":"Naina Kumar, I. Pradeep, Annapurna Srirambhatla, K. Poojitha, M. Mangla","doi":"10.2174/0115733947256172231128064128","DOIUrl":"https://doi.org/10.2174/0115733947256172231128064128","url":null,"abstract":"\u0000\u0000Bordeline Brenner tumors of the ovary are rare tumors accounting for 2% of\u0000all ovarian tumors and are characterized by the presence of papillary structures covered with transitional\u0000epithelium without or minimal stromal invasion.\u0000\u0000\u0000\u0000In the present case report a 60-year-old postmenopausal woman presented with\u0000complaints of lower abdominal pain and a right ovarian mass of 4x5cm, which was diagnosed on histopathological\u0000examination as borderline Brenner tumor of the ovary. There were coexisting nonatypical\u0000endometrial hyperplasia and endocervical polyps of 1.2x0.9x0.6cm, indicating endometrial\u0000hyperstimulation as a result of estrogen secreted by the tumor. The patient was managed successfully\u0000with staging laparotomy and was diagnosed with stage I borderline Brenner tumor with non-atypical\u0000endometrial hyperplasia and benign endocervical polyp.\u0000\u0000\u0000\u0000Borderline Brenner tumors are rare tumors of ovaries with uncertain malignant potential.\u0000They have no precise predictive markers but are known to produce estrogen. Surgery remains the\u0000mainstay of treatment for these tumors.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"5 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139881655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Malignant myxoid leiomyosarcoma (MMLS) is most commonly found in the uterus but can also occur in other areas, such as the extremities, vulva, chest wall, and abdominal cavity. This cancer is more prevalent in women and has a poor prognosis with a high rate of recurrence and a significant percentage of metastasis. Herein, we report the case of a 64-year-old female patient who presented with 3-month history of left lower abdominal mass. The patient underwent abdominal malignancy resection and was subsequently diagnosed with myxoid leiomyosarcoma. The patient experienced a recurrence and metastasis with significant ascites after the initial surgery and did not respond to treatment with oral Anrotinib in combination with Tislelizumab immunotherapy. Further genetic testing using next-generation sequencing (NGS) identified missense mutations in the PDGFRA and TP53 genes in the patient's plasma, but no mutations in the KIT gene were detected. Immunohistochemical analysis of the tumor tissue also revealed a negative expression of PD-L1. As a result, we altered her targeted therapy to Avapritinib, which resulted in significant improvement in her symptoms, including abdominal distension and pain, a decrease in ascites, and the KPS score increased from 60 points before treatment to 90 points after treatment SD (stable disease) was achieved for three months after treatment. In this case report, we present the instance of a patient with malignant myxoid leiomyosarcoma with a missense mutation in both the PDGFRA and TP53 genes. We found that targeted therapy with Avapritinib was effective in achieving a positive outcome in this patient. Our findings suggest that genetic detection is possible to better understand the biological behavior, genetic characteristics, and patient's response and tolerance to certain drugs, thus selecting the best treatment plan for the patient. Avapritinib may be a promising new treatment option for leiomyosarcoma patients with similar genetic mutations.
{"title":"Abdomen Malignant Myxoid Leiomyosarcoma with PDGFRA and TP53\u0000Missense Mutation: A Case Report","authors":"Yao-xuan Li, Jian-ping Yu, Yan-qing Gong, Hai-fu Huang, Xian-lin Wu","doi":"10.2174/0115733947276376231102103138","DOIUrl":"https://doi.org/10.2174/0115733947276376231102103138","url":null,"abstract":"\u0000\u0000Malignant myxoid leiomyosarcoma (MMLS) is most commonly found in\u0000the uterus but can also occur in other areas, such as the extremities, vulva, chest wall, and abdominal\u0000cavity. This cancer is more prevalent in women and has a poor prognosis with a high rate of recurrence and a significant percentage of metastasis.\u0000\u0000\u0000\u0000Herein, we report the case of a 64-year-old female patient who presented with\u00003-month history of left lower abdominal mass. The patient underwent abdominal malignancy resection and was subsequently diagnosed with myxoid leiomyosarcoma. The patient experienced a recurrence and metastasis with significant ascites after the initial surgery and did not respond to treatment\u0000with oral Anrotinib in combination with Tislelizumab immunotherapy. Further genetic testing using\u0000next-generation sequencing (NGS) identified missense mutations in the PDGFRA and TP53 genes in\u0000the patient's plasma, but no mutations in the KIT gene were detected. Immunohistochemical analysis\u0000of the tumor tissue also revealed a negative expression of PD-L1. As a result, we altered her targeted\u0000therapy to Avapritinib, which resulted in significant improvement in her symptoms, including abdominal distension and pain, a decrease in ascites, and the KPS score increased from 60 points before\u0000treatment to 90 points after treatment SD (stable disease) was achieved for three months after treatment.\u0000\u0000\u0000\u0000In this case report, we present the instance of a patient with malignant myxoid leiomyosarcoma with a missense mutation in both the PDGFRA and TP53 genes. We found that targeted\u0000therapy with Avapritinib was effective in achieving a positive outcome in this patient. Our findings\u0000suggest that genetic detection is possible to better understand the biological behavior, genetic characteristics, and patient's response and tolerance to certain drugs, thus selecting the best treatment plan\u0000for the patient. Avapritinib may be a promising new treatment option for leiomyosarcoma patients\u0000with similar genetic mutations.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"313 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140484548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-26DOI: 10.2174/0115733947279599231208095726
Archana, Rohitas Deshmukh
Colorectal cancer (CRC) ranks as the third most prevalent cancer type and the second leading cause of cancer-related deaths globally. The mortality rate from colon cancer has seen a significant increase, correlating with the widespread adoption of Western dietary habits and lifestyles. Medicinal plants, notably those containing functional phytochemicals like polysaccharides, exhibit antitumor and anti-apoptotic properties, offering potential for CRC prevention and treatment. Enhancing the efficacy of herbal medicines and addressing problems related to them could eventually become possible with the help of nanoscale drug delivery systems. Improved solubility and bioavailability, protection from toxicity, resistance to physical and chemical degradation, increased pharmacological activity, better distribution to tissue macrophages, and more stable are merely some of the benefits of developing nano dosage forms for herbal drugs in phyto-formulation research. The article has been drafted by gathering recent information available inScopus, ScienceDirect, Pubmed, Medline and Web of Science databases. The inclusion criterion was an English language article showing the effective use of whole plant or herbal products in CRC. Original articles and short communications on in vivo and in vitro experiments were included. Exclusion criteria included irrelevant studies, insufficient data, and mushroom or algae investigations. Case reports/case series, and letters to editors were not included but used to discover applicable primary material. This review suggests medicinal plants can produce anti-CRC chemicals. Herbs and spices with antiproliferative and angiogenesis-inhibiting properties may be useful as chemopreventive or chemotherapeutic therapies for colorectal cancer. This narrative review explores the usefulness of medicinal plants in the treatment of CRC using a novel drug delivery system. Nanotechnology is highlighted as a driving force behind the recent breakthroughs in CRC screening, diagnosis, and therapy. This review seeks to inform researchers on nanotechnology in CRC and inspire innovative nanotechnology-based therapies.
{"title":"Recent Advancement in Nanotechnological Approaches for Increasing\u0000the Effectiveness of Herbal Drugs in the Treatment of Colorectal Cancer","authors":"Archana, Rohitas Deshmukh","doi":"10.2174/0115733947279599231208095726","DOIUrl":"https://doi.org/10.2174/0115733947279599231208095726","url":null,"abstract":"\u0000\u0000Colorectal cancer (CRC) ranks as the third most prevalent cancer type and the second leading\u0000cause of cancer-related deaths globally. The mortality rate from colon cancer has seen a significant\u0000increase, correlating with the widespread adoption of Western dietary habits and lifestyles. Medicinal\u0000plants, notably those containing functional phytochemicals like polysaccharides, exhibit antitumor\u0000and anti-apoptotic properties, offering potential for CRC prevention and treatment. Enhancing\u0000the efficacy of herbal medicines and addressing problems related to them could eventually become\u0000possible with the help of nanoscale drug delivery systems. Improved solubility and bioavailability,\u0000protection from toxicity, resistance to physical and chemical degradation, increased pharmacological\u0000activity, better distribution to tissue macrophages, and more stable are merely some of the benefits of\u0000developing nano dosage forms for herbal drugs in phyto-formulation research. The article has been\u0000drafted by gathering recent information available inScopus, ScienceDirect, Pubmed, Medline and\u0000Web of Science databases. The inclusion criterion was an English language article showing the effective\u0000use of whole plant or herbal products in CRC. Original articles and short communications on in\u0000vivo and in vitro experiments were included. Exclusion criteria included irrelevant studies, insufficient\u0000data, and mushroom or algae investigations. Case reports/case series, and letters to editors were\u0000not included but used to discover applicable primary material. This review suggests medicinal plants\u0000can produce anti-CRC chemicals. Herbs and spices with antiproliferative and angiogenesis-inhibiting\u0000properties may be useful as chemopreventive or chemotherapeutic therapies for colorectal cancer.\u0000This narrative review explores the usefulness of medicinal plants in the treatment of CRC using a\u0000novel drug delivery system. Nanotechnology is highlighted as a driving force behind the recent\u0000breakthroughs in CRC screening, diagnosis, and therapy. This review seeks to inform researchers on\u0000nanotechnology in CRC and inspire innovative nanotechnology-based therapies.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"20 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140494274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-25DOI: 10.2174/0115733947265189231129105327
D. Patel, K. Patel
Atractylodes lancea Thunb. (Asteraceae) is a commonly used medicinal plant for gastric and appetite-associated complications in traditional Chinese medicine. The rhizome of Atractylodes lancea has been widely used for the treatment of human complications. Atractylodin has anti-angiogenic, anti-cancer, anti-inflammatory, anti-microbial, anti-pyretic and anti-hypertensive potential in medicine. Nano-formulations of atractylodin were also prepared in the scientific field to enhance its water solubility and efficacy in cholangiocarcinoma. Health-beneficial aspects of atractylodin in medicine have been investigated in the present work through collected scientific information on atractylodin from different literature databases. Scientific data on atractylodin has been collected from Google, Science Direct, Scopus, and PubMed. Further, detailed pharmacological activities and analytical aspects of atractylodin were discussed in this paper in order to know its biological potential in medicine. Analytical techniques of atractylodin were also discussed in the present work for separation, isolation, and identification of atractylodin. Scientific data analysis signified the biological importance of Atractylodes lancea Thunb. and its active phytochemical atractylodin in medicine. Scientific data signified the presence of atractylodin in Atractylodes lancea, Atractylodes chinensis, Atractylodes japonica, Atractylodes macrocephala, Atractylodes ovate and Atractylodis Rhizoma. Atractylodin has a significant biological effect on cholangiocarcinoma, hepatocellular carcinoma, breast cancer, lung cancer, cancer anorexiacachexia syndrome, colitis, rheumatoid arthritis, respiratory complications, GIT complications, hepatic complications, atopic dermatitis, aging process, neurodegenerative disease, calcified aortic valve disease, hypertension, pulmonary fibrosis, body temperature, olfactory neurons, podocyte hypermotility and toxicity. Further, its anti-nociceptive, anti-fibrotic, anti-angiogenic, anti-virulence, antibacterial, insecticidal, lipase inhibitory potential, immunomodulatory, and positive inotropic effects were also discussed in the present paper. Analytical techniques for the separation, isolation and identification of atractylodin in different samples were also discussed in the present work. The present work's scientific data signified the biological importance of atractylodin in medicine.
{"title":"Biological Potential and Therapeutic Effectiveness of a Polyethylene Alkyne Class Phytochemical ‘Atractylodin’ in Medicine for the Treatment\u0000of Cancer and other Human Complications","authors":"D. Patel, K. Patel","doi":"10.2174/0115733947265189231129105327","DOIUrl":"https://doi.org/10.2174/0115733947265189231129105327","url":null,"abstract":"\u0000\u0000Atractylodes lancea Thunb. (Asteraceae) is a commonly used medicinal\u0000plant for gastric and appetite-associated complications in traditional Chinese medicine. The rhizome\u0000of Atractylodes lancea has been widely used for the treatment of human complications. Atractylodin\u0000has anti-angiogenic, anti-cancer, anti-inflammatory, anti-microbial, anti-pyretic and anti-hypertensive\u0000potential in medicine. Nano-formulations of atractylodin were also prepared in the scientific field\u0000to enhance its water solubility and efficacy in cholangiocarcinoma.\u0000\u0000\u0000\u0000Health-beneficial aspects of atractylodin in medicine have been investigated in the present\u0000work through collected scientific information on atractylodin from different literature databases. Scientific\u0000data on atractylodin has been collected from Google, Science Direct, Scopus, and PubMed.\u0000Further, detailed pharmacological activities and analytical aspects of atractylodin were discussed in\u0000this paper in order to know its biological potential in medicine. Analytical techniques of atractylodin\u0000were also discussed in the present work for separation, isolation, and identification of atractylodin.\u0000\u0000\u0000\u0000Scientific data analysis signified the biological importance of Atractylodes lancea Thunb.\u0000and its active phytochemical atractylodin in medicine. Scientific data signified the presence of atractylodin\u0000in Atractylodes lancea, Atractylodes chinensis, Atractylodes japonica, Atractylodes macrocephala,\u0000Atractylodes ovate and Atractylodis Rhizoma. Atractylodin has a significant biological\u0000effect on cholangiocarcinoma, hepatocellular carcinoma, breast cancer, lung cancer, cancer anorexiacachexia\u0000syndrome, colitis, rheumatoid arthritis, respiratory complications, GIT complications, hepatic\u0000complications, atopic dermatitis, aging process, neurodegenerative disease, calcified aortic valve\u0000disease, hypertension, pulmonary fibrosis, body temperature, olfactory neurons, podocyte hypermotility\u0000and toxicity. Further, its anti-nociceptive, anti-fibrotic, anti-angiogenic, anti-virulence, antibacterial,\u0000insecticidal, lipase inhibitory potential, immunomodulatory, and positive inotropic effects\u0000were also discussed in the present paper. Analytical techniques for the separation, isolation and identification\u0000of atractylodin in different samples were also discussed in the present work.\u0000\u0000\u0000\u0000The present work's scientific data signified the biological importance of atractylodin in\u0000medicine.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"11 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140495093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-18DOI: 10.2174/0115733947274344231116113325
N. Jamali, Roohollah Mohseni, Mansoor Zareei, Javad Saffari-Chaleshtori
Cyclin-dependent kinases (CDKs) are serine/threonine kinase proteins that regulate the cell cycle through phosphorylation and dephosphorylation. These proteins are a main target in cancer therapy. This study investigated the effect of omeprazole on CDK2, CDK4, and CDK6 through simulation studies. To investigate the interaction between omeprazole and CDK2, 4, and 6, the threedimensional structure of omeprazole was obtained from PubChem, and the structures of CDK2, 4, and 6 were acquired from RCSB servers. The proteins were then simulated for 50 nanoseconds using the GROMACS 2021 platform before the docking process. Next, Autodock v.4.2.6 software was used to bind omeprazole as a ligand to these proteins, and a molecular dynamics simulation of the resulting protein-ligand complex was conducted using GROMACS after the docking process. Omeprazole exhibited a high affinity for interacting with CDK2, 4, and 6, mainly occurring in the ATP binding site of CDK4. However, the docking of omeprazole in the CDKs induced conformational changes in their structures, which could potentially affect their function and lead to cell cycle arrest. Omeprazole, which is a proton pump inhibitor, can induce cell cycle arrest by interacting with the ATP-binding site of CDK4. Moreover, it can also induce conformational changes in CDK2, CDK4, and CDK6 through high-affinity interactions with specific amino acid residues.
{"title":"The Molecular Docking and Molecular Dynamic Effects of Omeprazole on\u0000CDKs 2, 4, and 6 as a Potential CDK Inhibitor in Cancer Treatment","authors":"N. Jamali, Roohollah Mohseni, Mansoor Zareei, Javad Saffari-Chaleshtori","doi":"10.2174/0115733947274344231116113325","DOIUrl":"https://doi.org/10.2174/0115733947274344231116113325","url":null,"abstract":"\u0000\u0000Cyclin-dependent kinases (CDKs) are serine/threonine kinase proteins that\u0000regulate the cell cycle through phosphorylation and dephosphorylation. These proteins are a main\u0000target in cancer therapy. This study investigated the effect of omeprazole on CDK2, CDK4, and\u0000CDK6 through simulation studies.\u0000\u0000\u0000\u0000To investigate the interaction between omeprazole and CDK2, 4, and 6, the threedimensional structure of omeprazole was obtained from PubChem, and the structures of CDK2, 4, and 6 were acquired from RCSB servers. The proteins were then simulated for 50 nanoseconds using the GROMACS 2021 platform before the docking process. Next, Autodock v.4.2.6 software was used to bind omeprazole as a ligand to these proteins, and a molecular dynamics simulation of the resulting protein-ligand complex was conducted using GROMACS after the docking process.\u0000\u0000\u0000\u0000Omeprazole exhibited a high affinity for interacting with CDK2, 4, and 6, mainly occurring\u0000in the ATP binding site of CDK4. However, the docking of omeprazole in the CDKs induced conformational\u0000changes in their structures, which could potentially affect their function and lead to cell\u0000cycle arrest.\u0000\u0000\u0000\u0000Omeprazole, which is a proton pump inhibitor, can induce cell cycle arrest by interacting\u0000with the ATP-binding site of CDK4. Moreover, it can also induce conformational changes in\u0000CDK2, CDK4, and CDK6 through high-affinity interactions with specific amino acid residues.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"82 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139526420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-17DOI: 10.2174/0115733947270529231116114913
Mehdi Pezeshgi Modarres, Mohamad Amin Habibi, M. Pashaei, Yousef Mohammadpour, Kimia Jazi, S. Ahmadpour
Colorectal cancer (CRC) is a commonly diagnosed cancer responsible for numerous deaths worldwide. In recent decades, technological advances implicated in considering the molecular pathways underlying CRC pathogenesis. Several investigations have identified various mechanisms involved in CRC and have paved the way for new therapeutics and early diagnosis. Gut microbiome play a crucial role in intestinal inflammation and can be associated with colitis colorectal cancer. In this review, we narrated the role of the microbiome population and their metabolome profile as a new screening method for early detection of CRC.
{"title":"Alterations of the Gut Microbiome and Metabolome Following: A\u0000Opportunity for Early Detection of Colorectal Cancer","authors":"Mehdi Pezeshgi Modarres, Mohamad Amin Habibi, M. Pashaei, Yousef Mohammadpour, Kimia Jazi, S. Ahmadpour","doi":"10.2174/0115733947270529231116114913","DOIUrl":"https://doi.org/10.2174/0115733947270529231116114913","url":null,"abstract":"\u0000\u0000Colorectal cancer (CRC) is a commonly diagnosed cancer responsible for numerous deaths\u0000worldwide. In recent decades, technological advances implicated in considering the molecular pathways\u0000underlying CRC pathogenesis. Several investigations have identified various mechanisms involved\u0000in CRC and have paved the way for new therapeutics and early diagnosis. Gut microbiome\u0000play a crucial role in intestinal inflammation and can be associated with colitis colorectal cancer. In\u0000this review, we narrated the role of the microbiome population and their metabolome profile as a new\u0000screening method for early detection of CRC.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"37 7-8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140505605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-16DOI: 10.2174/0115733947263279231114111550
Raja Sharma, Satendra Kumar, Niranjan Kaushik, Bahadur Singh
Leukaemia, lymphoma, and myeloma are among the serious and frequently fatal conditions that impact thousands of people each year. Genetics, environmental factors, and medical problems can all affect the risk of developing blood cancer, however, the precise causes are still not entirely known. Fatigue, unexpected weight loss, and frequent infections are examples of common blood cancer symptoms. In the course of the diagnosis process, blood tests, imaging tests, and bone marrow biopsies are frequently combined. Blood cancer therapies include chemotherapy, radiation therapy, stem cell transplant, targeted therapy, and immunotherapy. Supportive care is also important for managing symptoms and improving quality of life. Ongoing research is exploring new treatments and therapies for blood cancer, as well as ways to improve supportive care and personalize treatment plans. Blood cancer patients and their families have severe emotional and psychological effects that must not be ignored. For improving outcomes and raising the general standard of living for people affected by this condition, it is essential to address these needs.
{"title":"Decoding the Mistry of Blood Cancer cause and diagnosis of management.","authors":"Raja Sharma, Satendra Kumar, Niranjan Kaushik, Bahadur Singh","doi":"10.2174/0115733947263279231114111550","DOIUrl":"https://doi.org/10.2174/0115733947263279231114111550","url":null,"abstract":"\u0000\u0000Leukaemia, lymphoma, and myeloma are among the serious and frequently fatal conditions\u0000that impact thousands of people each year. Genetics, environmental factors, and medical problems\u0000can all affect the risk of developing blood cancer, however, the precise causes are still not entirely\u0000known. Fatigue, unexpected weight loss, and frequent infections are examples of common\u0000blood cancer symptoms. In the course of the diagnosis process, blood tests, imaging tests, and bone\u0000marrow biopsies are frequently combined. Blood cancer therapies include chemotherapy, radiation\u0000therapy, stem cell transplant, targeted therapy, and immunotherapy. Supportive care is also important\u0000for managing symptoms and improving quality of life. Ongoing research is exploring new treatments\u0000and therapies for blood cancer, as well as ways to improve supportive care and personalize treatment\u0000plans. Blood cancer patients and their families have severe emotional and psychological effects that\u0000must not be ignored. For improving outcomes and raising the general standard of living for people\u0000affected by this condition, it is essential to address these needs.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"14 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140506268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.2174/0115733947266657231114075805
Priyanka Bajpai, Phool Chandra
The second most prevalent cause of fatalities globally is malignant tumors. The avoidance and therapy of cancer proliferation still have many prospects for betterment despite enormous advancements. Chemotherapy can occasionally have a lot of unfavorable adverse reactions. Novel agents from botanicals, especially the use of cancer therapeutic ingredients, may decrease negative consequences. There are currently several products from plants used for fighting cancer. However, numerous plant chemicals have not yet been examined in people but show extremely encouraging invitro anti-cancer properties. Further research is required to determine whether these plant chemicals are beneficial in treating human cancers. The present work has focused on the various traditional herbal remedies and the phytochemicals that exhibited promising anticancer impact. The desirable activity may be due to novel agents isolated from plant sources. The present investigations address natural ingredients for cancer treatment and chemoprevention that are now being used in clinical settings and/or are undergoing clinical studies. Potential research concentrating on naturally anticancer drugs can create an entirely novel avenue in the fight against cancer that could significantly boost the chance of survival for cancer patients.
{"title":"Relevance of Conventional Herbal Remedies in the Prevention and Treatment\u0000of Malignant Tumors: Looking Toward the Future","authors":"Priyanka Bajpai, Phool Chandra","doi":"10.2174/0115733947266657231114075805","DOIUrl":"https://doi.org/10.2174/0115733947266657231114075805","url":null,"abstract":"\u0000\u0000The second most prevalent cause of fatalities globally is malignant tumors.\u0000The avoidance and therapy of cancer proliferation still have many prospects for betterment despite\u0000enormous advancements. Chemotherapy can occasionally have a lot of unfavorable adverse reactions.\u0000Novel agents from botanicals, especially the use of cancer therapeutic ingredients, may decrease negative\u0000consequences.\u0000\u0000\u0000\u0000There are currently several products from plants used for fighting cancer. However, numerous\u0000plant chemicals have not yet been examined in people but show extremely encouraging invitro\u0000anti-cancer properties. Further research is required to determine whether these plant chemicals\u0000are beneficial in treating human cancers.\u0000\u0000\u0000\u0000The present work has focused on the various traditional herbal remedies and the phytochemicals\u0000that exhibited promising anticancer impact. The desirable activity may be due to novel agents\u0000isolated from plant sources.\u0000\u0000\u0000\u0000The present investigations address natural ingredients for cancer treatment and chemoprevention\u0000that are now being used in clinical settings and/or are undergoing clinical studies. Potential\u0000research concentrating on naturally anticancer drugs can create an entirely novel avenue in the\u0000fight against cancer that could significantly boost the chance of survival for cancer patients.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"6 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140508459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：